CALR (Calreticulin) Exon 9 Mutation Analysis by PCR
2010673
Ordering Recommendation
Use for diagnostic and prognostic information in patients with myeloproliferative neoplasms (MPNs) when JAK2 testing is negative.
Mnemonic
CALR
Methodology
Polymerase Chain Reaction/Capillary Electrophoresis
Performed
DNA isolation: Sun-Sat
Assay: Sun, Tue-Fri
Assay: Sun, Tue-Fri
Reported
2-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
- Patient Preparation
- Collect
- Lavender (EDTA) OR bone marrow (EDTA).
- Specimen Preparation
- Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) OR Transport 3 mL bone marrow. (Min: 1 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.
- Remarks
- Stability
- Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
Reference Interval
Interpretive Data
Refer to report.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2010674 | CALR Exon 9 Mutation Analysis - Source | 31208-2 |
| 2010675 | CALR Exon 9 Mutation Analysis - Result | 35474-6 |
Aliases
- CALR
- ET
- JAK2-negative myeloproliferative neoplasm
- MPD
- MPL
- MPN
- Myeloproliferative disorders
- PMF